Reports have shown that FTY720, a PP2A-activating drug reduced neuroinflammation in experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis [107], and is clinically used to treat the relapsing form of MS [108]. This evidence concerns the gene PTPA and multiple sclerosis.